Loading
Loading
Metabolic & Body Composition · 60mg
Choose dose
Janoshik-tested · 10 vials per kit
Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, studied in clinical research for its broad metabolic profile. Research has examined its potential to enhance satiety, suppress hunger, and increase energy expenditure. Studies have also explored improvements in cardiometabolic markers including HbA1c, fasting glucose, cholesterol, triglycerides, and non-alcoholic fatty liver disease.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Chemical Properties
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
Retatrutide
Retatrutide (LY3437943) is a triple incretin receptor agonist — the first synthetic peptide to simultaneously target GLP-1, GIP, and glucagon receptors (GcgR) in a single molecule. Developed by Eli Lilly, it represents the third generation of incretin pharmacology beyond dual agonists, adding a thermogenic dimension through glucagon receptor engagement that earlier generations lack.
Retatrutide activates all three receptors with approximately equipotent nanomolar affinity. GLP-1R engagement contributes appetite suppression and glucose-dependent insulin secretion. GIPR engagement adds adipose tissue effects and amplifies the GLP-1R appetite signal. Crucially, glucagon receptor activation stimulates energy expenditure through GcgR-mediated thermogenesis and lipolysis — an effect counterbalanced by concurrent GLP-1R activity that prevents net hyperglycaemia. This triple mechanism distinguishes retatrutide from dual agonists in both the magnitude of weight loss and the composition of weight lost.
Phase 2 data published in the NEJM (2023) demonstrated up to 24.2% body weight reduction at 48 weeks — among the highest observed for any pharmacological agent in obesity trials. Research continues into non-alcoholic fatty liver disease/NASH, dyslipidaemia, insulin resistance, and cardiovascular risk reduction. The glucagon component makes retatrutide a candidate for hepatic conditions where glucagon signalling plays a regulatory role.
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
